Catalent to double biomanufacturing capacity with $200m investment

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Sitthiphong)
(Image: Getty/Sitthiphong)

Related tags: Catalent

Catalent will use the funds to enlarge drug substance manufacturing and drug product fill/finish capacity.

The $200m (€173m) investment will take place at Catalent’s biologics manufacturing sites in Madison, Wisconsin, and Bloomington, Indiana. The decision follows the expansion of its biologics packaging capacity​, at the latter site.

The improvement upon current capacity in drug substance manufacturing and fill/finish will take place over three years.

It will see mammalian cell culture capacity increased with two new suites, each housing a two 2,000 litre single-use bioreactor system. Fill/finish capacity will be increased by an expanded Bloomington site, which will grow by 79,000-sq-ft to accommodate a high-speed flexible vial line operating at 300 units per minute.

Brian Riley, VP of operations, biologics and specialty drug delivery at Catalent, told us that the expansion is required to meet increasing demand in the late-stage clinical and commercial supply phases.

“The Bloomington facility recently achieved regulatory approval for a twentieth commercial product, so part of the expansion at both sites is necessary to fulfil increasing demand from existing customers’ programs, but the expansion is also in anticipation of new business too​,” Riley explained.

The upgrade to both facilities will also add new staff members over the coming years. Riley could not specify a precise number but said, “we anticipate adding over 100 new roles in Madison, and up to 200 new jobs in Bloomington by the end of 2024.

Catalent acquired the Bloomington facility as part of its $950m takeover of Cook Pharmica​ in 2017. Subsequently, the company revealed that it would be looking to the site, with it operating at 45% of its capacity​ upon acquisition.

Related news

Related products

show more

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

CadenceILC_610x343

Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars